News Headlines Article

Insurance debate snares prostate study
Philadelphia Inquirer

More than a decade after prostate cancer became the economic driver behind proton beam therapy in the U.S., it still isn’t clear that men treated with the technology do better than those who get less costly radiation treatments.

That’s why expert groups have recently advised against insurance coverage of proton therapy for prostate cancer – and why some private plans are refusing to pay for it.